Market capitalization | $535.61m |
Enterprise Value | $547.06m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 140.63 |
EV/Sales (TTM) EV/Sales | 1.20 |
P/S ratio (TTM) P/S ratio | 1.18 |
P/B ratio (TTM) P/B ratio | 1.92 |
Revenue growth (TTM) Revenue growth | 1.34% |
Revenue (TTM) Revenue | $455.04m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
4 Analysts have issued a Organogenesis Holdings forecast:
4 Analysts have issued a Organogenesis Holdings forecast:
Sep '24 |
+/-
%
|
||
Revenue | 455 455 |
1%
1%
|
|
Gross Profit | 325 325 |
1%
1%
|
|
EBITDA | 37 37 |
20%
20%
|
EBIT (Operating Income) EBIT | 12 12 |
52%
52%
|
Net Profit | -7.38 -7.38 |
157%
157%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.
Head office | United States |
CEO | Gary Gillheeney |
Employees | 862 |
Founded | 1985 |
Website | www.organogenesis.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.